Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
- 31 May 1997
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 26 (5) , 961-966
- https://doi.org/10.1016/s0168-8278(97)80103-1
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Meta-analysis: An introduction and point of viewHepatology, 1996
- Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis CGastroenterology, 1995
- A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B HepatitisNew England Journal of Medicine, 1995
- HCV RNA serum levels, genotypes and response to alpha interferon treatment in chronic hepatitis CGastroenterology, 1995
- Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-αJournal of Viral Hepatitis, 1995
- What options are left when hepatitis C does not respond to interferon? Placebo-controlled benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferonJournal of Hepatology, 1994
- Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypesJournal of Hepatology, 1994
- A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis CGastroenterology, 1994
- Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type CJournal of Hepatology, 1993
- Ribavirin treatment for chronic hepatitis CThe Lancet, 1991